These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 2347659)

  • 41. Effect of one haemodialysis treatment on the plasma concentrations of intact parathyroid hormone and ionised calcium: usefulness of end-dialysis values in evaluating the suppressibility of hyperparathyroidism.
    Pietilä K; Mustonen J; Mörsky P; Seppälä E; Pasternack A; Koivula T
    Nephrol Dial Transplant; 1989; 4(2):115-8. PubMed ID: 2496352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Total parathyroidectomy: parathyroid hormone levels and supernumerary glands in hemodialysis patients.
    Meakins JL; Milne CA; Hollomby DJ; Goltzman D
    Clin Invest Med; 1984; 7(1):21-5. PubMed ID: 6723120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Correlation of serum Bio-intact PTH (1-84) and parathyroid gland size in hemodialysed patients].
    Inaba M; Imanishi Y; Ueda M; Cho H; Tahara H; Ishimura E; Nishizawa Y; Yamakawa T; Okuno S
    Clin Calcium; 2005 Sep; 15 Suppl 1():64-6; discussion 66-7. PubMed ID: 16272632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxicity of parathyroid hormone in uremia.
    Klahr S; Slatopolsky E
    Annu Rev Med; 1986; 37():71-8. PubMed ID: 3010810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fundamental and clinical evaluation on PTH mid-region RIA kit (PTH kit "YAMASA") for serum PTH].
    Togashi K; Fujita S; Ando K; Marumo F
    Rinsho Byori; 1988 Aug; 36(8):974-8. PubMed ID: 3241426
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
    Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calcium-dependent release of N-terminal fragments and intact immunoreactive parathyroid hormone by human pathological parathyroid tissue in vitro.
    el-Hajj Fuleihan G; Chen CJ; Rivkees SA; Marynick SP; Stock J; Pallotta JA; Brown EM
    J Clin Endocrinol Metab; 1989 Oct; 69(4):860-7. PubMed ID: 2778039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and application of a mid-region specific assay for human parathyroid hormone.
    Gleed JH; Hendy GN; Nussbaum SR; Rosenblatt M; O'Riordan JL
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):365-73. PubMed ID: 3742832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Values of intact serum parathyroid hormone in different stages of renal insufficiency.
    Hellman P; Backman U; Danielson BG; Akerström G; Rastad J; Wide L; Ljunghall S
    Scand J Urol Nephrol; 1991; 25(3):227-32. PubMed ID: 1947852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Radioimmunologic determination of circulating parathyroid hormone in patients with primary and secondary hyperparathyroidism].
    Lo Giudice C; Cascone C; Manente P; Gasparoni P; De Luca M; Rota G; Conte N
    Minerva Med; 1982 Dec; 73(48):3425-8. PubMed ID: 7177469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of intravenous calcitriol on platelet intracellular calcium in uremic hemodialysis patients with secondary hyperparathyroidism.
    Lin SH; Shieh SD; Chyr SH; Lu KC; Lin YF; Diang LK; Chou TC; Ding YA
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Oct; 54(4):240-5. PubMed ID: 7982134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of the molecular forms of immunoreactive parathyroid hormone in primary hyperparathyroidism and in hyperparathyroidism due to renal failure.
    Gautvik KM; Gautvik VT; Halvorsen JF
    Scand J Clin Lab Invest; 1983 Nov; 43(7):553-64. PubMed ID: 6658372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneity of carboxyl-terminal parathyroid hormone circulating forms in patients with hyperparathyroidism due to end stage renal disease.
    Vieira JG; Kunii IS; Ohe MN; Carvalho AB
    Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1074-8. PubMed ID: 20126864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay.
    Blind E; Schmidt-Gayk H; Scharla S; Flentje D; Fischer S; Göhring U; Hitzler W
    J Clin Endocrinol Metab; 1988 Aug; 67(2):353-60. PubMed ID: 3292561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia.
    Brandi L; Daugaard H; Egsmose C; Tvedegaard E; Kjaerulff Nielsen P; Olgaard K
    J Intern Med; 1996 Apr; 239(4):353-60. PubMed ID: 8774390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.